LIBERTY LAKE, Wash., March 30, 2016 -- Hunt Mining Corp. ("Hunt" or the "Company") (TSXV:HMX) is pleased to provide an update regarding the ongoing activities in Argentina.
Hunt Mining announces it has shipped ore samples taken from its flagship project, La Josefina in Santa Cruz Province, Argentina to the McClelland Laboratories in Sparks, Nevada.
The principal purpose of the tests on the ore samples is to confirm the compatibility of additional La Josefina veins for flotation processing and to test procedures allowing for onsite bullion generation.
“With the more favorable conditions being created by the newly elected President Macri, new Mines Secretary Daniel Meilán, and the optimism within the Santa Cruz Province, we are enthusiastic about the future of precious metals mining in Argentina,” stated Tim Hunt, Executive Chairman/CEO.
About Hunt Mining
Hunt Mining Corp. has continued to develop its properties as an active and aggressive explorer in Santa Cruz since 2006. During that time, Hunt's wholly owned subsidiary, Cerro Cazador S.A., has completed exploration activity including 62,000 meters of HQ core drilling, 416 line kilometers of Induced Polarization geophysical surveys and more than 20,000 surface soil, sediment, channel, chip, and trench samples, beyond the historical work previous to the same properties. This, and additional information can be viewed at www.huntmining.com.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking statements. The Company has provided the forward-looking statements in reliance on assumptions that it believes are reasonable at this time. The reader is cautioned that the assumptions used in the preparation of the forward-looking statements may prove to be incorrect. All such forward-looking statements involve substantial known and unknown risks and uncertainties, certain of which are beyond the Company’s control. Such risks and uncertainties include, without limitation, delays resulting from or inability to obtain required regulatory approval. The actual results, performance or achievements could differ materially from those expressed in, or implied by, these forward-looking statements and, accordingly, no assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do, what benefits, including the amount of proceeds, the Company will derive therefrom. Readers are cautioned that the foregoing list of factors is not exhaustive.
For more information contact: Bob Little Chief Financial Officer T: (509) 290 5659 E: [email protected]


U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 



